This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have boosted Q2 performance amid the coronavirus pandemic.
Invitae (NVTA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Genetic testing is likely to drive Invitae's (NVTA) Q2 earnings.
Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?
by Zacks Equity Research
Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.
Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.
Aphria (APHA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Aphria's (APHA) fiscal fourth-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter performance is likely to reflect growth in its five global business units.
What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) top line is likely to have benefited from a robust CAG business and regulatory approvals for its COVID-19 tests.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance within net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in Q2.
Emergent (EBS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Emergent's (EBS) upcoming Q2 earnings conference, investors will focus on the company's CDMO collaborations to help partners manufacture a vaccine against COVID-19.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.
Cerner (CERN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) second-quarter results are likely to reflect solid show by Subscriptions, Managed Services and Licensed software segments.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.
Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q2.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Deferred Procedures to Mar Boston Scientific (BSX) Q2 Earnings
by Zacks Equity Research
With lockdowns continuing through all three months of the second quarter, Boston Scientific (BSX) is expected to have faced a more dreadful time.
Quest Diagnostics' (DGX) Q2 Earnings Beat, Volume Declines
by Zacks Equity Research
Following the guidance withdrawal last quarter, Quest Diagnostics (DGX) provides its full-year projection alongside Q2 earnings release.
PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment. However, forex remained a woe.
Align Technology (ALGN) Earnings Fall Shy of Estimates in Q2
by Zacks Equity Research
Align Technology's (ALGN) segments report COVID-19-led lower sales across major geographies.
ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q2.
Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?
by Zacks Equity Research
Strength in segmental business is likely to have aided Hologic's (HOLX) performance in third-quarter fiscal 2020 amid the coronavirus-led economic doldrums.